Incidence and Mortality of Parkinson’s Disease in Estonia

  title={Incidence and Mortality of Parkinson’s Disease in Estonia},
  author={L. Kadastik-Eerme and N. Taba and T. Asser and P. Taba},
  pages={63 - 72}
Background: There is lack of data on the incidence of Parkinson’s disease (PD) based on repeat studies. Mortality rates of PD in Estonia have never been studied before. Objectives: To estimate the incidence and mortality rates of PD in Estonia, to compare current incidence rates with those of the prior epidemiological study in Estonia, and to examine the reported causes of death of the study population. Methods: Eligible subjects were identified from multiple case-finding sources. Subjects were… Expand
2 Citations
Transcriptomic profiles in Parkinson’s disease
For the first time a meta-analysis is applied on transcriptomic sample sets in Parkinson’s disease, exploring the notion that Parkinson's disease is not just a neuronal tissue disease by exploring peripheral tissues and comparing post mortem brain tissue and blood results. Expand


Incidence of Parkinson’s Disease in Estonia
The incidence of Parkinson’s disease was studied over a 9-year period (1990–1998) in Tartu county, Estonia, with a mean population of 156,417, except for a slightly higher incidence rate in the urban compared with the rural population in Estonia. Expand
Incidence of Parkinson’s disease in Norway: the Norwegian ParkWest study
Female gender was associated with a considerably lower risk of PD and slightly delayed motor onset but had no impact on severity of parkinsonism or clinical phenotype in incident drug naïve PD, suggesting that the female gender influences on the nigrostriatal system are most pronounced in the preclinical phase of the disease. Expand
Incidence and mortality of Parkinson's disease in older Canadians.
Incidence of PD is substantially higher in advanced age with age adjusted increases for both all-cause and injury mortalities and falls as a primary factor for injury mortality in PD are highlighted. Expand
Incidence of Parkinson's disease and atypical parkinsonism: Russian population‐based study
The incidence of Parkinson's disease in the Russian population was slightly lower than in studies of Western populations and the male‐to‐female ratio was closer to those reported in studies from Asia. Expand
Time trends in the prevalence and incidence of Parkinson's disease in Taiwan: A nationwide, population-based study.
An increasing trend in the annual prevalence rates of PD is identified; however, the substantial decline in the incidence of PD suggests that some major environmental risk factors for PD were removed from this population during this time period. Expand
The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis
PD incidence generally increases with age, although it may stabilize in those who are 80+, which may be explained by methodological differences between studies. Expand
Trends in the Incidence of Parkinson Disease in the General Population: The Rotterdam Study.
The incidence of parkinsonism in general and of PD in particular, decreased between 1990 and 2011, and competitive event rates were lower in the 2000 subcohort, and mortality rates among persons with parkinsonist remained stable. Expand
Time Trends in the Incidence of Parkinson Disease.
The study suggests that the incidence of parkinsonism and PD may have increased between 1976 and 2005, particularly in men 70 years and older, and is associated with the dramatic changes in smoking behavior that took place in the second half of the 20th century. Expand
Incidence of Parkinson’s Disease in Bulgaria
The incidence of Parkinson’s disease was studied over a 3-year period (2002–2004) in the district of Plovdiv, Bulgaria with a mean population of 713,090 and the diagnosis PD was based on UK PD Society Brain Bank Criteria. Expand
Mortality from Parkinson's disease in China: Findings from a ten-year follow up study in Shanghai.
This finding confirms the similar survival of patients with PD to the control population in the post-levodopa era and predicts poor survival in this cohort of PD patients subsequent to 10 years of surveillance in Shanghai, China. Expand